Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 60P 002; UK 80067

Latest Information Update: 06 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer 60 Degrees Pharmaceuticals Australia; Pfizer
  • Class Antiasthmatics; Antivirals; Dihydropyridines; Imidazoles; Small molecules
  • Mechanism of Action Calcium channel antagonists; Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Dengue
  • Discontinued Asthma

Most Recent Events

  • 06 Mar 2019 Modipafant is still in phase I trials for Dengue in USA (60 degrees pharmaceuticals pipeline, March 2019)
  • 28 Oct 2018 No recent reports of development identified for phase-I development in Dengue in USA
  • 14 May 2018 60 Degree Pharmaceuticals plans a phase II trial for Dengue (60 Degrees pipeline, May 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top